Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Durability of ALKS 3831 in Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder
2017-000918-36Phase 3Completed
- Sponsor
- Alkermes
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olanzapine + samidorphan in schizophrenia, schizophreniform disorder and bipolar I disorder, sponsored by Alkermes. Primary endpoint: Frequency of serious and non-serious adverse events. Started May 2017; status: completed.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophreniaschizophreniform disorderbipolar I disorder
Beyond the preview
Go deeper on 2017-000918-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000918-36.